Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Prasugrel No Match For Clots Compared To Plavix, Bristol Says

This article was originally published in The Pink Sheet Daily

Executive Summary

In contrast to Lilly, Bristol management says it expects FDA to schedule an advisory committee review for the Plavix competitor.
Advertisement

Related Content

Bristol Sells ConvaTec Wound Care For $4.1 Billion
Bristol Sells ConvaTec Wound Care For $4.1 Billion
North American Erbitux Sales Up 17 Percent In First Quarter
North American Erbitux Sales Up 17 Percent In First Quarter
Prasugrel Sales Force Poised For FDA Decision In June, Lilly Says
Prasugrel Sales Force Poised For FDA Decision In June, Lilly Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS067654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel